NFKB1 and diffuse large B-cell lymphoma: On-going trials in DLBCL include Bortezomib (targeting NF-kB), Ibrutinib (targeting BTK) and Lenalidomide (an immunomodulatory agent) in combination with R-CHOP and as maintenance therapies [45].